Arcutis Biotherapeutics/$ARQT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Ticker
$ARQT
Sector
Primary listing
Employees
354
Headquarters
Website
ARQT Metrics
BasicAdvanced
$2.6bn
-
-$0.02
1.59
-
Price and volume
Market cap
$2.6bn
Beta
1.59
52-week high
$31.77
52-week low
$12.72
Average daily volume
1.7m
Financial strength
Current ratio
2.684
Quick ratio
2.257
Long term debt to equity
56.273
Total debt to equity
60.465
Interest coverage (TTM)
0.24%
Profitability
EBITDA (TTM)
5.463
Gross margin (TTM)
90.94%
Net profit margin (TTM)
-0.57%
Operating margin (TTM)
0.77%
Effective tax rate (TTM)
-70.81%
Revenue per employee (TTM)
$1,170,000
Management effectiveness
Return on assets (TTM)
0.50%
Return on equity (TTM)
-1.43%
Valuation
Price to revenue (TTM)
6.428
Price to book
13.75
Price to tangible book (TTM)
14.87
Price to free cash flow (TTM)
157.925
Free cash flow yield (TTM)
0.63%
Free cash flow per share (TTM)
0.132
Growth
Revenue change (TTM)
95.29%
Earnings per share change (TTM)
-98.22%
3-year revenue growth (CAGR)
300.56%
3-year earnings per share growth (CAGR)
-85.16%
What the Analysts think about ARQT
Analyst ratings (Buy, Hold, Sell) for Arcutis Biotherapeutics stock.
ARQT Financial Performance
Revenues and expenses
ARQT Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs